SpringWorks Therapeutics, Inc. - common stock (SWTX)
SWTX moved a median of +0.02% 30 minutes after news, and +0.09% by the close. How SWTX actually reacts to news — the realized, point-in-time move the market made, measured across 233 labeled events over the last three years with zero look-ahead.
SWTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 45% | 202 |
| 30-min | +0.02% | 51% | 202 |
| 60-min | -0.02% | 48% | 202 |
| to close | +0.09% | 55% | 202 |
| Middle 50% of SWTX reactions | -1.09% to +0.52% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 233 |
Half of all SpringWorks Therapeutics, Inc. - common stock news events land between -1.09% and +0.52% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SWTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 13 | +0.03% | 92% | +0.20% |
| Rating reiterations | 43 | +0.03% | 56% | +0.20% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SWTX ranks against every other measured name →
That’s how SWTX usually reacts — get an email when it moves on news →Email me when SWTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SWTX's baseline. Nothing else.
Recent SWTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology | Press release | GlobeNewswire | — | — | |
| European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors | Press release | GlobeNewswire | — | — | |
| European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN | Press release | GlobeNewswire | — | — | |
| Form 15-12G SpringWorks Therapeutics | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K SpringWorks Therapeutics For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POSASR SpringWorks Therapeutics | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS SpringWorks Therapeutics | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K SpringWorks Therapeutics For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K SpringWorks Therapeutics For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | +0.02% | |
| Form DEFA14A SpringWorks Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.04% | +0.02% | |
| Form DEFM14A SpringWorks Therapeutics | SEC filing · Form DEFM14A | SEC EDGAR | +0.20% | +0.28% | |
| SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN | Press release | GlobeNewswire | +0.09% | +0.48% | |
| Form PREM14A SpringWorks Therapeutics For: May 15 | SEC filing · Form PREM14A | SEC EDGAR | -0.04% | -0.17% | |
| Form 8-K SpringWorks Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | -0.35% | |
| Form 10-Q SpringWorks Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.07% | -0.13% | |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc. | Press release | PR Newswire | +0.00% | +0.20% | |
| Form 8-K SpringWorks Therapeutics For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | +0.09% | |
| Form DEFA14A SpringWorks Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -0.11% | +0.09% | |
| Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business | Press release | GlobeNewswire | -0.11% | +0.09% | |
| Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business | Press release | Business Wire | -0.11% | +0.09% | |
| SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.11% | +0.09% | |
| SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union | Press release | GlobeNewswire | -0.11% | +0.09% | |
| Form ARS SpringWorks Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.07% | -1.10% | |
| Form DEF 14A SpringWorks Therapeutics For: May 14 | SEC filing · Form DEF | SEC EDGAR | -1.07% | -1.10% | |
| Form DEFA14A SpringWorks Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -1.07% | -1.10% | |
| Form 10-K SpringWorks Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.85% | -2.81% | |
| Form 8-K SpringWorks Therapeutics For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | -2.85% | -2.81% | |
| Form S-8 SpringWorks Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -2.85% | -2.81% | |
| SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | Press release | GlobeNewswire | -2.85% | -2.81% | |
| SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over | Press release | PR Newswire | -1.08% | -1.34% | |
| Form 8-K SpringWorks Therapeutics For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | +3.71% | |
| SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN | Press release | GlobeNewswire | -0.10% | +3.71% | |
| UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN | Press release | GlobeNewswire | -0.10% | +3.71% | |
| SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | Press release | GlobeNewswire | -0.71% | +1.75% | |
| Form 8-K SpringWorks Therapeutics For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -4.22% | -4.47% | |
| SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -4.22% | -4.47% | |
| SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.02% | +5.76% | |
| SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference | Press release | GlobeNewswire | +0.76% | +4.38% | |
| Form 10-Q SpringWorks Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.15% | +10.37% | |
| Form 8-K SpringWorks Therapeutics For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +7.15% | +10.37% | |
| SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +7.15% | +10.37% | |
| SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference | Press release | GlobeNewswire | +7.15% | +10.37% | |
| SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting | Press release | GlobeNewswire | +1.49% | -3.12% | |
| SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology | Press release | GlobeNewswire | +1.49% | -3.12% | |
| SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting | Press release | GlobeNewswire | +0.40% | +0.73% | |
| SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference | Press release | GlobeNewswire | +0.23% | +3.37% | |
| Process over Projects: Rethinking GxP System Validation in an Age of Rapid Change, Upcoming Webinar Hosted by Xtalks | Press release | PR Web | -0.40% | +0.71% | |
| SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 | Press release | GlobeNewswire | +0.90% | -1.15% | |
| FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | Press release | GlobeNewswire | +0.02% | +0.29% | |
| Form 10-Q SpringWorks Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.46% | -15.18% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SWTX section they belong to.
Where else SWTX is measured.
SWTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is SpringWorks Therapeutics, Inc. - common stock's median reaction calculated?
Every labeled SWTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 233 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of SWTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SWTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.